Cutera (NASDAQ:CUTR) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm presently has a $41.00 target price on the medical device company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 9.57% from the stock’s previous close.
According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
Separately, Piper Sandler lifted their price target on shares of Cutera from $28.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, February 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $32.25.
Shares of CUTR traded up $0.39 during trading hours on Tuesday, reaching $37.42. 235,317 shares of the stock traded hands, compared to its average volume of 150,141. The company has a current ratio of 2.13, a quick ratio of 1.48 and a debt-to-equity ratio of 0.14. Cutera has a 52-week low of $9.07 and a 52-week high of $37.87. The company’s 50-day moving average price is $28.06 and its two-hundred day moving average price is $21.95. The company has a market cap of $659.83 million, a P/E ratio of -20.67 and a beta of 1.60.
Cutera (NASDAQ:CUTR) last released its earnings results on Tuesday, February 16th. The medical device company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.42. Cutera had a negative net margin of 18.83% and a negative return on equity of 61.21%. On average, research analysts forecast that Cutera will post -1.76 EPS for the current year.
Institutional investors have recently bought and sold shares of the company. Vantage Consulting Group Inc bought a new stake in shares of Cutera in the 4th quarter worth about $56,000. BNP Paribas Arbitrage SA grew its holdings in Cutera by 358.8% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 4,271 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 3,340 shares during the last quarter. Citigroup Inc. grew its holdings in Cutera by 248.8% during the 4th quarter. Citigroup Inc. now owns 4,193 shares of the medical device company’s stock valued at $101,000 after purchasing an additional 2,991 shares during the last quarter. State of Tennessee Treasury Department grew its holdings in Cutera by 24.3% during the 3rd quarter. State of Tennessee Treasury Department now owns 5,852 shares of the medical device company’s stock valued at $111,000 after purchasing an additional 1,145 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in Cutera by 28.6% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 7,185 shares of the medical device company’s stock valued at $136,000 after purchasing an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 87.79% of the company’s stock.
Cutera, Inc, a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women’s intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars.
See Also: What is cost of equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]